Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients
Recruitment status was: Recruiting
Clinical and experimental evidences suggests an immunomodulatory effect of sex hormones in multiple sclerosis.
The role of oral estroprogestins in the pathogenesis and in the clinical course of the disease is actually unknown.
The aim of the study is to investigate safety and tolerability of association of estroprogestins in two different doses with interferon-beta 1a in patients with relapsing-remitting multiple sclerosis.
|Multiple Sclerosis||Drug: estroprogestins Drug: interferon-beta 1a||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis|
- Safety assessment at 6, 12, 18 and 24 months, including adverse events, physical examination and laboratory parameters
- Relapse rate at 6, 12, 18 and 24 months,
- EDSS progression at 12 and 24 months,
- MS functional composite score at 12 and 24 months,
- Number and volume of new gad-enhancing lesions at 12 and 24 months
- Number of new T1 and T2 lesions at 12 and 24 months
- Brain volume changes at 12 and 24 months
- Neuropsychological examination at 0, 12, 24 months
- Hamilton scale for depression score at 0, 12, 24 months
- MS Quality of Life scale score(MSQOL54)at 0, 12, 24 months
- Fatigue Severity Scale score at 0, 12, 24 months
|Study Start Date:||May 2002|
|Estimated Study Completion Date:||December 2008|
Phase 2, randomised, single blind, three arms study.
Follow-up of 24 months.
The study will include relapsing-remitting multiple sclerosis female patients.
Patients will be equally randomised into three groups: 1) patients treated with IFN-beta 1a (44 mcg for three times a week), 2) patients treated with IFN-beta 1a and lower-dose estroprogestins (desogestrel 150 mcg, etinilestradiol 20 mcg), 3) patients treated with IFN-beta 1a and higher-dose estroprogestins (desogestrel 25 mcg, etinilestradiol 40 mcg).
Safety and tolerability of the treatment will be evaluated using neurological examination and MRI analysis.
A complete neurological examination (with EDSS) will be performed at month 0, 6, 12, 18 and 24.
MRI examination will be assessed at baseline and at month 12 and 24. In the same day of MRI examination we'll collect blood samples for hormonal analysis (we'll measure sex hormones in the follicular and in the luteal phase of a single menstrual cycle).
During the follow-up patients will be evaluated also with: MS-Functional Composite at month 0, 6, 12, 18, 24; neuropsychological evaluation at month 0, 12, 24; Fatigue Severity Scale at month 0, 12, 24; Hamilton Depression Scale at month 0, 12, 24; Quality of Life scale (MSQOL54) at month 0, 12, 24.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00151801
|Contact: Carlo Pozzilli, MDemail@example.com|
|Contact: Fabiana Marinelli, MDfirstname.lastname@example.org|
|Department of Neurology - University of Rome La Sapienza||Recruiting|
|Rome, Italy, 00100|
|Contact: Carlo Pozzilli, MD +39-06-49914716 email@example.com|
|Contact: Fabiana Marinelli, MD +39-338-2955443 firstname.lastname@example.org|
|Principal Investigator: Fabiana Marinelli, MD|
|Sub-Investigator: Laura De Giglio, MD|
|Study Chair:||Valentina Tomassini, MD||Department of Neurological Science University of Rome "La Sapienza"|
|Principal Investigator:||Fabiana Marinelli, MD||Department of Neurological Science, University of Rome "La Sapienza"|
|Study Director:||Carlo Pozzilli, MD||Department of Neurological Science, University of Rome "La Sapienza"|